Skip to main content
Clinical Trials/NCT05906368
NCT05906368
Completed
Not Applicable

Hypotension Prediction Index to Predict Epidural-labor Analgesia Induced Hypotension -- Pilot Study

Grace Lim, MD, MS1 site in 1 country34 target enrollmentApril 18, 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Anesthesia, Epidural
Sponsor
Grace Lim, MD, MS
Enrollment
34
Locations
1
Primary Endpoint
Time-to-treatment of Hypotension (Minutes)
Status
Completed
Last Updated
5 months ago

Overview

Brief Summary

The purpose of this pilot trial is to examine the feasibility and ease of use of monitoring by ClearSight in laboring and delivering patients with the intent to compare time-to-treatment of hypotension between conventionally monitored patients (Group CM) and those receiving HPI (Group CM + HPI) monitoring by ClearSight, in a population of healthy laboring women who receive epidural analgesia.

Detailed Description

In a prospective study, we will achieve the following aims: To determine the feasibility and ease of use of the ClearSight monitoring system in the labor-delivery room (LDR) in detecting and monitoring hypotensive events post-epidural labor analgesia placement. To compare the Time-to-Treatment of hypotensive events between the conventionally monitored patients (Group CM) and those receiving HPI (Group CM + HPI) monitoring by ClearSight.

Registry
clinicaltrials.gov
Start Date
April 18, 2024
End Date
August 29, 2024
Last Updated
5 months ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Sponsor
Grace Lim, MD, MS
Responsible Party
Sponsor Investigator
Principal Investigator

Grace Lim, MD, MS

Associate Professor, Chief Obstetric & Women's Anesthesiology

University of Pittsburgh

Eligibility Criteria

Inclusion Criteria

  • Age ≥ 18 years of age
  • Planning vaginal delivery
  • Receiving epidural labor analgesia (ELA)

Exclusion Criteria

  • Non-reassuring fetal tracing at the time of ELA request
  • Contraindications to ELA
  • Significant cardiac arrhythmias or aortic regurgitation
  • Arrhythmia
  • Treatment with antihypertensive medications
  • Pre-eclampsia with or without severe features
  • Preoperative infection
  • Inability to use ClearSight device for any reason
  • Non-English fluency
  • Sustains unintentional dural puncture

Outcomes

Primary Outcomes

Time-to-treatment of Hypotension (Minutes)

Time Frame: From epidural placement until 4-hours post-infusion start

The difference in time between diagnosis of hypotension and treatment by clinical staff between CM and HPI groups

Ease of Use by Clinical Staff

Time Frame: report at 4-hour post-infusion

Clinical nurse reports of ease of use of ClearSight device. This outcome will be measured on a Likert Scale (0-4) with the options being: 0-Completely Disagree, 1-Disagree, 2-Neither agree nor disagree, 3-Agree, 4-Completely Agree. Outcome measure will be reported as count of participant's responses per category. For this scale, the objective was to obtain agreeable response feedback (score of 3 or 4). The specific question to measure ease of use by clinical staff was: "The ClearSight blood pressure monitoring device seems easy to use."

Ease of Hypotension Detection by Clinical Staff

Time Frame: report at 4-hour post-infusion

Clinical nurse reports of ease of hypotension detection using ClearSight device. This outcome will be measured on a Likert Scale (0-4) with the options being: 0-Completely Disagree, 1-Disagree, 2-Neither agree nor disagree, 3-Agree, 4-Completely Agree. Outcome measure will be reported as count of participant's responses per category. For this scale, the objective was to obtain agreeable response feedback (score of 3 or 4). The specific question to measure ease of use by clinical staff was: "The ClearSight blood pressure monitoring device seems suitable."

Satisfaction of ClearSight Use by Clinical Staff

Time Frame: report at 4-hour post-infusion

Clinical nurse reports of satisfaction of use of ClearSight device. This outcome will be measured on a Likert Scale (0-4) with the options being: 0-Completely Disagree, 1-Disagree, 2-Neither agree nor disagree, 3-Agree, 4-Completely Agree. Outcome measure will be reported as count of participant's responses per category. For this scale, the objective was to obtain agreeable response feedback (score of 3 or 4). The specific question to measure ease of use by clinical staff was: "The ClearSight blood pressure monitoring device meets my approval."

Secondary Outcomes

  • Total Intravenous Fluids, mL(Epidural placement to 4-hours post-infusion start)
  • Total Number of Reported Changes in Fetal Heart Rate Category (From Healthy to Deceleration or Excelleration)(Epidural placement to 4-hours post-infusion start)
  • Total Time in Hypotension With Mean Arterial Pressure (MAP) <65 mmHg (in Minutes)(Epidural placement to 4-hours post-infusion start)
  • Nausea (Yes/No)(Epidural placement to 4-hours post-infusion start)
  • Vomiting (Yes/No)(Epidural placement to 4-hours post-infusion start)
  • Total Phenylephrine, mg(Epidural placement to 4-hours post-infusion start)
  • Total Ephedrine, mg(Epidural placement to 4-hours post-infusion start)
  • Fetal Heart Rate Decelerations Within 1 Hour of Initiation of ELA(Epidural placement to 1-hour post-infusion start)

Study Sites (1)

Loading locations...

Similar Trials